CryoLife (NYSE: CRY) and VWR Corporation (NASDAQ:VWR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CryoLife and VWR Corporation, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CryoLife 0 0 3 0 3.00
VWR Corporation 0 3 1 0 2.25

CryoLife presently has a consensus price target of $22.33, indicating a potential upside of 2.68%. VWR Corporation has a consensus price target of $29.00, indicating a potential downside of 12.31%. Given CryoLife’s stronger consensus rating and higher probable upside, research analysts clearly believe CryoLife is more favorable than VWR Corporation.

Volatility & Risk

CryoLife has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, VWR Corporation has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Valuation & Earnings

This table compares CryoLife and VWR Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
CryoLife $183.16 million 3.97 $23.56 million $0.33 65.91
VWR Corporation $4.58 billion 0.95 $492.10 million $1.08 30.62

VWR Corporation has higher revenue and earnings than CryoLife. VWR Corporation is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.


This table compares CryoLife and VWR Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CryoLife 6.16% 7.41% 4.95%
VWR Corporation 3.12% 15.54% 4.69%

Insider and Institutional Ownership

68.9% of CryoLife shares are held by institutional investors. 6.0% of CryoLife shares are held by company insiders. Comparatively, 35.5% of VWR Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


CryoLife beats VWR Corporation on 8 of the 14 factors compared between the two stocks.

CryoLife Company Profile

CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.

VWR Corporation Company Profile

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC. The Americas segment consists of operations located principally in the United States and Canada, as well as in Puerto Rico, Mexico and select countries in Central and South America, including Costa Rica, Brazil, Argentina and Chile. As of December 31, 2016, the Americas segment included 67 facilities located in eight countries. As of December 31, 2016, the EMEA-APAC segment consisted of its operations located principally in Europe, as well as in certain Asia-Pacific countries, and included 110 facilities located in 26 countries. The Company’s portfolio includes chemicals, reagents, consumables, durable products and scientific equipment and instruments.

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with's FREE daily email newsletter.